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As the world embarks on the largest vaccination program 
in history, it is worth reflecting on the huge logistical effort 
this will involve. Vaccination remains the strongest tool in 
the public health armamentarium for prevention of infec-
tious diseases, but achieving herd immunity will require 
population vaccination rates of around 70%. Apart from the 
huge clinical delivery and manufacturing efforts required to 
achieve this, successful inoculation efforts will also depend 
on addressing vaccine hesitancy and misinformation.
Some vaccines have previously been associated with 
the occurrence of rare, immune-mediated adverse events, 
although these can sometimes be difficult to separate from 
the overall infection burden at the time. However, we will 
need to remain vigilant for those events which may have 
occurred as a consequence of Covid-19 vaccination, as even 
very low-frequency events may have significant health bur-
dens in the context of the number of anticipated vaccina-
tions. It is important to note that study data available to date 
for the Covid-19 vaccination program remains reassuring.
In this month’s journal club, we review some articles that 
explore the association of neurological complications associ-
ated with large-scale vaccination events, as well as immune 
response to vaccination in the context of a modern therapeu-
tic agent. The first is a phase IIIb trial assessing the impact 
of ocrelizumab on vaccine response in people with multiple 
sclerosis (pwMS). The second is a case–control study that 
set out to investigate the hypothesis that vaccination is a risk 
factor for MS, and the last is a study reporting on the asso-
ciation between influenza vaccination and Guillain-Barré 
syndrome (GBS).
Effect of ocrelizumab on vaccine responses 
in patients with multiple sclerosis: 
the VELOCE study
It is thought that selected disease-modifying therapies 
(DMTs) for MS may lead to a significant increase in risk 
of infection because of their mode of action, and it is estab-
lished that infections can be associated with high morbidity 
as well as disease progression. However, patients on DMTs 
may mount a lower immune response to vaccination, in par-
ticular those on B cell-depleting drugs. This study is a phase 
IIIb trial assessing the impact of Ocrelizumab-induced B cell 
depletion on vaccination response in pwMS. Ocrelizumab is 
a CD20-selective humanized monoclonal antibody licenced 
for use in relapsing and primary progressive MS, adminis-
tered in 6 monthly infusions.
The study recruited 68 participants with MS receiving 
ocrelizumab 600 mg (as a first dose) and 34 in a control 
group (either on interferon beta or no DMT) vaccinated 
with tetanus toxoid (TT)-containing vaccine, Pneumovax 
[23-valent pneumococcal polysaccharide vaccine (23-
PPV)], and keyhole limpet hemocyanin (KLH). The ocreli-
zumab group were randomized to either receiving Prevnar 
(a 13-valent conjugate pneumococcal vaccine) as a booster 
4 weeks after Pneumovax (OCR1 group, n = 33), or an influ-
enza vaccine (OCR2 group, n = 35). The control group also 
received the influenza vaccine. Vaccinations were adminis-
tered 12 weeks after ocrelizumab infusions.
Primary endpoint was the proportion of patients with 
positive response to TT-containing booster (defined as an 
antibody titre ≥ 0.2 IU/mL or ≥ fourfold increase in titre 
if pre-vaccination levels were ≥ 0.1 IU/mL) 8 weeks after 
vaccination. In the ocrelizumab group, positive response 
rate to TT vaccine was 23.9% at 8 weeks (vs 54.5% in the 
control group). Response to ≥ 5 serotypes in the 23-PPV at 
4 weeks was 71.6 vs 100% in the ocrelizumab and control 
groups, respectively. Response to the influenza vaccine was 
reduced in the OCR2 (55.6–80.0%) vs the control group 
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(75.0–97.0%). Humoral response to KLH (a highly immuno-
genic T cell-dependent antigen used commonly in immuno-
toxicological studies) was also decreased in the ocrelizumab 
group. No safety issues were identified in either group. The 
study also noted that ocrelizumab-treated patients maintain 
their pre-treatment specific humoral immunity to common 
viral and bacterial antigens.
Comment: This study demonstrated that non-live vac-
cines given at least 12 weeks after Ocrelizumab infusion can 
still result in an appropriate, although attenuated, immune 
response and provide sustained seroprotection in pwMS. The 
12-week interval was chosen to investigate the effect of com-
plete peripheral B cell depletion on the immune response 
to vaccinations, due to the long half-life of the anti-CD20 
antibody.
The authors conclude that vaccination should be recom-
mended for all patients on ocrelizumab, including with the 
annual seasonal influenza vaccine as an appropriate protec-
tive humoral response can be expected. Live or live-atten-
uated vaccines were not studied and are not recommended 
following ocrelizumab.
B a r- O r  A  e t   a l .  Ne u ro l o g y.  2 0 2 0  O c t 
6;95(14):e1999–e2008. https:// doi. org/ 10. 1212/ WNL. 00000 
00000 010380.
A large case–control study on vaccination 
as risk factor for multiple sclerosis
There remains considerable controversy on whether vaccina-
tion can trigger disease progression or exacerbation in MS 
or be a causative factor in disease initiation. Studies to date 
have shown conflicting results. The aim of this case–control 
study was to investigate the hypothesis that vaccination is a 
risk factor for MS using retrospective analysis of ambulatory 
claims data of 223,035 participants < 70 years old (12,262 
patients with MS and 210,773 controls), held by the Bavar-
ian Association of Statutory Health Insurance Physicians 
(BASHIP).
A cohort of newly diagnosed pwMS and two control 
cohorts of participants diagnosed with other autoimmune 
diseases (Crohn’s disease and psoriasis) were identified 
using registered ICD-10 diagnosis codes. Additional con-
trols without these diagnoses (n = 83,610) were matched to 
the MS cohort in a 5:1 ratio. Inclusion in the MS cohort 
required a recorded neurologist visit and no diagnosis of a 
clinically isolated syndrome (CIS) before or after MS diag-
nosis. The authors focused on the 5-year period prior to diag-
nosis, during which any recorded reimbursement claim for 
vaccination, or combinations of vaccination, was included. 
Association between vaccination and MS was assessed using 
unconditional logistic regression models and odds ratios. 
The analysis was repeated for various time frames (quartiles) 
in the 5-year period prior to diagnosis.
There was a lower odds ratio for MS in participants with 
any vaccination, consistent across all studied time frames 
and control cohorts. A low rate of vaccination in the months 
preceding an MS diagnosis was also identified, arguing 
against a major role of vaccination in triggering relapses. 
The negative association of vaccines with MS was present 
for all reported vaccinations and specifically for influenza, 
hepatitis B, and Tick-Borne Encephalitis.
Comment: This large case–control study demonstrates a 
lower rate of vaccination in the 5 years preceding MS onset, 
supporting the hypothesis that vaccination is not a factor 
in MS onset. The size of the cohort is a particular strength. 
Although the study was anchored to time of diagnosis, the 
authors used strict definitions of MS (requiring less than 
one neurologic consultation or MRI in the 5-year period, 
and no diagnosis of optic neuritis). The results of this study 
provide further evidence against the role of vaccination as 
an aetiological factor for MS.
H a p fe l m e i e r  A  e t   a l .  N e u r o l o g y.  Au g 
2019;93(9):e908–e916. https:// doi. org/ 10. 1212/ WNL. 00000 
00000 008012.
Guillain–Barré syndrome after high‑dose 
influenza vaccine administration 
in the United States, 2018–2019 season
Following the 1976 US influenza vaccination program, when 
an increased risk of GBS was identified, seasonal influenza 
vaccine programs have been actively surveyed for adverse 
events. Most of these studies have found either no risk or 
a small increase in risk of around 1–3 additional cases per 
million vaccinees; a risk significantly lower than the risk of 
GBS caused by influenza itself.
This study investigated the risk of GBS during the 
2018–2019 season using the Medicare database after the 
Vaccine Safety Datalink (VSD) project identified a possi-
ble early statistical signal. The VSD then conducted weekly 
rapid cycle analysis to monitor risk of GBS following sea-
sonal high-dose influenza vaccination (IIV3-HD). End-of-
season nonsequential chart-confirmed self-controlled risk 
interval analyses (SCRI) involved 646,996 IIV3-HD vac-
cinations and yielded a RR of 1.00 (95% CI 0.06–15.99). 
The  observed number of GBS cases occurring in the 
1–42 days after IIV3-HD administration was also com-
pared with post-vaccination rate in prior influenza seasons 
(2012–2016), with no increased risk identified.
An early and end-of-season SCRI was then conducted 
among 14,437,945 (all seasonal vaccines combined of which 
8,667,640 were IIV3-HD) influenza-vaccinated Medicare 
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beneficiaries aged ≥ 65 years to compare number of GBS 
cases in days 1–42 post-vaccination (risk window) with 
that in days 43–84 post-vaccination (control window). In 
the end-of-season analyses, there was no statistically signifi-
cant increase in GBS risk observed in either the 8–21 days 
post-vaccination (OR 1.64; 95% CI 0.92–2.91) or 1–42 days 
post-vaccination (OR 1.12; 95% CI 0.70–1.79) risk win-
dows. These estimates did not change after seasonality 
adjustments.
In summary, no statistically significant increased risk of 
GBS following IIV3-HD was identified for the 2018–2019 
season.
Comment: Although this study did not exclude an asso-
ciation between 2018 and 2019 IIV3-HD and GBS, it was 
able to determine that if such a risk existed, it was reassur-
ingly low. Studies have repeatedly demonstrated a stronger 
association between a preceding viral illness and GBS; and 
the benefits of influenza vaccination appear to greatly out-
weigh the risk.
Perez-Vilar S et  al. J Infect Dis. 2021 Feb 
13;223(3):416–425. https:// doi. org/ 10. 1093/ infdis/ jiaa5 43.
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